Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme hails ‘excellent’ first quarter progress

Merck Sharpe and Dohme hails ‘excellent’ first quarter progress

5th May 2010

Merck Sharpe and Dohme has expressed satisfaction with the progress it has made in the first quarter of 2010.

The pharmaceutical company achieved a worldwide sales total of $11.4 billion (7.5 billion pounds) during the quarter, which is significantly ahead of its 2009 performance due to the integration of product lines from Schering-Plough.

These include brands such as Singulair, Januvia and Isentress, all of which saw double-digit year-on-year sales growth, while mature Merck products such as Zostavax and Maxalt also experienced gains.

Merck Sharpe and Dohme now expects to achieve a full year revenue total of between $45.4 billion and $46.4 billion.

Richard Clark, the company’s chairman and chief executive officer, said: “The first full quarter of results for the new Merck reflect our strong focus on driving revenue growth, maintaining the momentum of the business and reducing our cost structure.”

Last week, Merck Sharpe and Dohme appointed Kenneth Frazier as the company’s new president, taking over a role previously occupied by Mr Clark.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.